Global
Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fanconi
Anemia - Pipeline Review, H1 2018, provides an overview of the Fanconi
Anemia (Hematological Disorders) pipeline landscape.
Fanconi anemia (fan-KO-nee uh-NEE-me-uh),
or FA, is a rare, inherited blood disorder that leads to bone marrow failure.
The disorder also is called Fanconi's anemia. FA is a type of aplastic anemia.
In aplastic anemia, the bone marrow stops making or doesn't make enough of all
three types of blood cells. Low levels of the three types of blood cells can
harm many of the body's organs, tissues, and systems. Treatment is recommended
for significant cytopenias, such as hemoglobin less than 8 g/dL, platelets
fewer than 500/?L.
Global
Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fanconi
Anemia - Pipeline Review, H1 2018, provides comprehensive information on the
therapeutics under development for Fanconi Anemia (Hematological Disorders),
complete with analysis by stage of development, drug target, mechanism of
action (MoA), route of administration (RoA) and molecule type. The guide covers
the descriptive pharmacological action of the therapeutics, its complete
research and development history and latest news and press releases.
The Fanconi
Anemia (Hematological Disorders) pipeline guide also reviews of key players
involved in therapeutic development for Fanconi Anemia and features dormant and
discontinued projects. The guide covers therapeutics under Development by
Companies /Universities /Institutes, the molecules developed by Companies in
Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 3 and 1
respectively. Similarly, the Universities portfolio in Phase II and Preclinical
stages comprises 2 and 2 molecules, respectively.
Fanconi
Anemia (Hematological Disorders) pipeline guide helps in identifying and
tracking emerging players in the market and their portfolios, enhances decision
making capabilities and helps to create effective counter strategies to gain
competitive advantage. The guide is built using data and information sourced
from Global Markets Direct's proprietary databases, company/university
websites, clinical trial registries, conferences, SEC filings, investor
presentations and featured press releases from company/university sites and
industry-specific third party sources. Additionally, various dynamic tracking
processes ensure that the most recent developments are captured on a real time
basis.
The
pipeline guide provides a snapshot of the global therapeutic landscape of
Fanconi Anemia (Hematological Disorders).
The pipeline guide reviews
pipeline therapeutics for Fanconi Anemia (Hematological Disorders) by companies
and universities/research institutes based on information derived from company
and industry-specific sources.
The pipeline guide covers
pipeline products based on several stages of development ranging from
pre-registration till discovery and undisclosed stages.
The pipeline guide features
descriptive drug profiles for the pipeline products which comprise, product
description, descriptive licensing and collaboration details, R&D brief,
MoA & other developmental activities.
The pipeline guide reviews key
companies involved in Fanconi Anemia (Hematological Disorders) therapeutics and
enlists all their major and minor projects.
The pipeline guide evaluates
Fanconi Anemia (Hematological Disorders) therapeutics based on mechanism of
action (MoA), drug target, route of administration (RoA) and molecule type.
The pipeline guide encapsulates
all the dormant and discontinued pipeline projects.
The pipeline guide reviews latest
news related to pipeline therapeutics for Fanconi Anemia (Hematological
Disorders).
Procure strategically
important competitor information, analysis, and insights to formulate effective
R&D strategies.
Recognize
emerging players with potentially strong product portfolio and create effective
counter-strategies to gain competitive advantage.
Find and recognize significant
and varied types of therapeutics under development for Fanconi Anemia
(Hematological Disorders).
Classify potential new clients or
partners in the target demographic.
Develop
tactical initiatives by understanding the focus areas of leading companies.
Plan mergers
and acquisitions meritoriously by identifying key players and it's most
promising pipeline therapeutics.
Formulate corrective measures for
pipeline projects by understanding Fanconi Anemia (Hematological Disorders)
pipeline depth and focus of Indication therapeutics.
Develop and design in-licensing
and out-licensing strategies by identifying prospective partners with the most
attractive projects to enhance and expand business potential and scope.
Adjust the therapeutic portfolio
by recognizing discontinued projects and understand from the know-how what
drove them from pipeline.
For more information on the research report,
refer to below link:
Related Reports:
Ken Research
Ankur Gupta, Head Marketing & Communications
Sales@kenresearch.com
+91-9015378249
